Immunotherapy plus chemoradiation shows promise for inoperable esophageal cancer
NCT ID NCT03777813
First seen Nov 18, 2025 · Last updated Apr 30, 2026 · Updated 17 times
Summary
This study tested whether adding the immunotherapy drug durvalumab to standard chemoradiation helps people with unresectable esophageal cancer. 112 participants received either chemoradiation alone or chemoradiation plus durvalumab, followed by durvalumab maintenance. The main goal was to see if the combination delays cancer growth or improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGUS CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Rangueil Larrey
Toulouse, France
-
Centre Hospitalier Universitaire
Poitiers, France
-
Centre Oscar Lambret, CLCC UNICANCER
Lille, France
-
Centre Paul Strauss, CLCC UNICANCER
Strasbourg, France
-
Hôpital Haut-Lévêque
Pessac, 33604, France
-
Hôpital Saint Louis, APHP
Paris, 75010, France
-
Iuct, Clcc Unicancer
Toulouse, 31059, France
Conditions
Explore the condition pages connected to this study.